NGS equipment delivers comprehensive genomic data with exceptional accuracy and speed. We utilize these advanced sequencing technologies to analyze millions of DNA & RNA fragments simultaneously, providing a detailed view of the entire genome. This allows us to identify genetic variations associated with cancer. Our process is highly scalable, enabling us to analyze large datasets from diverse populations.

Our proprietary AI-driven biomarker discovery platform analyzes complex genomic data to identify patterns and predict health outcomes. We use machine learning to identify subtle variations that may be missed by traditional methods. Our AI platform provides personalized insights that can inform clinical decision-making and improve patient care.

Moreover, we are committed to ethical AI development, ensuring that our algorithms are transparent, unbiased, and secure. We also utilize AI to help in the process of ensuring that the data is representative of all populations.